Skip to main content

Table 2 Summary of the pooled results from meta-analysis

From: A meta-analysis and The Cancer Genome Atlas data of prostate cancer risk and prognosis using epithelial cell adhesion molecule (EpCAM) expression

Group

Studies

Cancer samples

Nonmalignant samples

OR with 95% CI

P

SE

Cancer vs. Benign

3

175

170

77.93 (4.90–1238.45)

0.002

1.411

Cancer vs. Normal

2

33

30

161.61 (17.65–1479.55)

< 0.001

1.13

Clinicopathological characteristics

 Gleason score (≥ 7 vs. ≤ 6)

2

430

 

0.48 (0.27–0.85)

0.012

0.293

 T stage (T3–4 vs. T1–2)

2

427

 

1.75 (0.78–3.91)

0.175

0.411

 Lymph node metastasis (Positive vs. Negative)

2

430

 

27.89 (0.004–1.7e+ 05)

0.455

4.481

 Bone metastasis (Positive vs. Negative)

2

59

 

145.80 (14.58–1458.02)

< 0.001

1.175

  1. OR odds ratio, 95% CI 95% confidence interval, SE standard error
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us